Epcoritamab (Tepkinly®). HTA ID: 24010

Assessment Status Rapid Review Complete
HTA ID 24010
Drug Epcoritamab
Brand Tepkinly®
Indication Epcoritamab (Tepkinly®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Assessment Process
Rapid review commissioned 11/03/2024
Rapid review completed 15/04/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of epcoritamab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.